6533b835fe1ef96bd129f49a
RESEARCH PRODUCT
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy
Jorge LabradorElisa LunoEdo VellengaSalut BrunetJose Gonzalez-camposeMaria C. ChillonAleksandra HolowieckaJordi EsteveJuan BerguaJose D. Gonzalez-sanmiguelCristina GilM. TormoOlga SalameroFelix MansoIsolda FernandezJavier De LasernaMaria-jose MorenoM. Perez-encinasIsabel KrsnikJosep-maria RiberaJose CerveraMaria J. CalasanzBlanca BoludaMarta SobasBob LowenbergMiguel A. SanzPau MontesinosL. PalmerFernandezS. CiarloF. BezaresF. RojasH. LongoniM. GelemurP. FazioC. CanepaS. SabaG. BalladaresP. NegriM. GiuntaJ. MiloneM. PratesD. LafalseC. SossaF. JaramilloJ. MayerF. RamosJ. MartinezM. R. De GrootH. C. Schoutensubject
MaleCancer Researchcomplex karyotypeANTHRACYCLINE MONOCHEMOTHERAPYmedicine.medical_treatmentAbnormal KaryotypechemotherapyGastroenterologyLeukocyte Count0302 clinical medicineLeukemia Promyelocytic AcuteRecurrenceAcute promyelocytic leukemiaAntineoplastic Combined Chemotherapy ProtocolsPROGNOSTIC-SIGNIFICANCECumulative incidenceATRAChildIn Situ Hybridization FluorescenceAged 80 and overrelapsePETHEMAIncidence (epidemiology)ADDITIONAL CHROMOSOME-ABNORMALITIESAge FactorsHematologyMiddle AgedPrognosisARSENIC TRIOXIDEFLT3 MUTATIONSLeukemiaTreatment OutcomeOncologyChild Preschool030220 oncology & carcinogenesisCytogenetic AnalysisFemaleAdultAcute promyelocytic leukemiamedicine.medical_specialtyCYTOGENETIC CHANGESAdolescentYoung Adult03 medical and health sciencesInternal medicineStatistical significanceComplex KaryotypemedicineHumansClinical significanceAgedCONSOLIDATION THERAPYChromosome AberrationsChemotherapybusiness.industrymedicine.diseaseRISK-ADAPTED TREATMENTTRANS-RETINOIC ACIDATRA Acute promyelocytic leukemia chemotherapy complex karyotype prognostic relapsebusinessprognostic030215 immunologydescription
Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of ≥2 ACA, and a very CK (CK+) as ≥3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with <2 ACA (p=.09). Among patients with CK+, the 5-year CIR was 27% vs 12% (p=.003), retaining the statistical significance in multivariate analysis. This study shows an increased risk of relapse among APL patients with CK + treated with ATRA plus chemotherapy front-line regimens.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-04-16 | Leukemia & Lymphoma |